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Abstract
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Previous studies have identified the immunological functions of transcription factor B
lymphocyte-induced maturation protein-1 (Blimp-1) in various adaptive immune cell types such as
T and B lymphocytes. More recently, it has been shown that Blimp-1 extends its functional roles
to dendritic cells (DCs) and macrophages, two cell types belonging to the innate immune system.
The protein acts as a direct and indirect regulator of target genes by recruiting chromatin
modification factors and by regulating microRNA expression, respectively. In DCs, Blimp-1 has
been identified as one of the components involved in antigen presentation. Genome-wide
association studies identified polymorphisms associated with multiple autoimmune diseases such
as system lupus erythematosus, rheumatoid arthritis, and inflammatory bowel disease in PRDM1,
the gene encoding Blimp-1 protein. In this review, we will discuss the immune regulatory
functions of Blimp-1 in DCs with a main focus on the tolerogenic mechanisms of Blimp-1
required to protect against the development of autoimmune diseases.
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Discovery of Blimp-1
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B lymphocyte-induced maturation protein-1 (Blimp-1) was first identified and characterized
in human cDNA clones by Maniatis and colleagues [1] followed by the discovery of murine
Blimp-1 by Davis and colleagues three years later [2]. Human PR domain containing 1 with
zinc finger domain (PRDM1) (a gene encoding Blimp-1 protein) is located at chromosome
6q21 and contains 789 amino acids. Murine Prdm1 is located at 10qB2 and contains 856
amino acids. Despite the fact that murine Blimp-1 contains 67 additional amino acids at the
N-terminus, the human and mouse proteins are highly homologous and are interchangeable
in functional assays [3]. Structural analysis clearly shows the similarity between human and
mouse Blimp-1 protein; both contain zinc finger DNA-binding domains, a proline-rich
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region (PR) and an acidic region. Although five zinc finger motifs are implicated in DNA
binding, only the first two zinc finger motifs are necessary for recognition of positive
regulatory domain I (PRDI) in the IFNβ promoter [4]. The DNA consensus sequence of
Blimp-1 was determined and is very similar to that of interferon regulatory factor (IRF) 1
and IRF2 [1, 4, 5]. In fact, Blimp-1 is induced upon virus infection, and Blimp-1 and IRF1/2
compete for binding to the IRF binding site in the IFNβ promoter [5].

Author Manuscript

The PR domain in Blimp-1 has similarities with the SET domain found in histone methyl
transferases (HMT) [6]. Although the PR domain of Blimp-1 does not have HMT activity,
Blimp-1 can recruit the G9a HMT to the IFNb promoter as in the osteosarcoma cell line
U2OS in which ectopic expression of Blimp-1 represses IFNβ expression through the
recruitment of G9a, which induces repressive histone modification at lysine 9 on histone 3
(H3K9) [7]. In primordial germ cells, Blimp-1 complexed with prmt5, an arginine HMT,
which catalyzes dimethylation of arginine 3 on H2A and H4 [8]. More recently, Blimp-1 has
been shown to regulate gene expression in CD8 T cells by recruitment of G9a and histone
deacetylase 2 (HDAC2) [9]. These studies suggest that Blimp-1 acts as a transcriptional
repressor of target genes through its recruitment of histone modulating co-repressors to
create a more compact chromatin structure.

Author Manuscript

What induces Blimp-1 expression? Activation of pattern recognition receptors and their
respective signaling pathways positively regulates Blimp-1 expression in B and T
lymphocytes [1]. This was first demonstrated in viral infection experiments in which
Blimp-1 transcription was induced upon Sendai virus infection in the U20S cell line.
Lipopolysaccharide (LPS), which is a Toll-like receptor (TLR) 4 agonist, is a strong inducer
of Blimp-1 expression in splenic B cells and B-1 B cells [10, 11]. TLR9 activation induces
Blimp-1 expression in mouse marginal zone (MZ) B cells and B-1 B cells [12] and in human
naïve B cells, transitional B cells, and chronic lymphocytic leukemia (CLL) cells [13–15].
Several cytokines induce Blimp-1 expression including IL-2, IL-4, IL-6, IL-10, and IL-21
via signal transducer and activator of transcription 3 (STAT3), strongly implicating STAT3
as a direct regulator of Blimp-1 expression [16–19]. Two other transcription factors,
interferon responsive factor 4 (IRF4) and activator protein-1 (AP-1), can bind directly to the
PRDM1 promoter region and activate its transcription [20–23] (summary Table 1: Signals
induce Blimp-1 expression).

Blimp-1 as a risk factor in autoimmune diseases

Author Manuscript

Genome-wide association studies (GWAS) have been used to assay thousands of individuals
identifying hundreds of single nucleotide polymorphism (SNP) associations with over 80
diseases (http://www.genome.gov/gwastudies). Initial GWAS identified approximately 50
gene loci with polymorphisms which predispose to SLE (review in [24]). This study
confirmed the genes that were previously identified to be associated with SLE, for example
human leukocyte antigen (HLA) molecules [25, 26]. The identified genes could be grouped
into three functional categories: interferon-alpha (IFNα) signaling pathway, lymphocyte
activation signaling pathways, and apoptotic cell clearance pathway. Genes belonging to the
IFNα signaling pathway include Toll-like receptor (TLR) 7 [27], IRF5 [28], signal
transducer and activator of transcription 4 (STAT4) [29], interleukin-1 receptor-associated
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kinase 1 (IRAK1) [30], and tumor necrosis factor-induced protein 3 (TNFAIP3) [31]. Genes
belonging to lymphocyte activation signaling pathway play roles in regulation and
suppression of lymphocyte activation, including protein tyrosine phosphatase, non-receptor
type 22 (PTPN22) [32], programmed cell death protein 1 (PD-1) [33], LYN [34], and B
lymphocyte kinase (BLK) [35, 36]. Polymorphisms in another group of genes are involved
in apoptotic cell clearance, including C1q [37], FcgammaRIIA [38], C-reactive protein
(CRP) [39], FcRIIB [40, 41], and integrin alpha M (ITGAM) [42, 43].

Author Manuscript

SNPs in the intergenic region between PRDM1 and autophagy 5(ATG5) have been identified
as candidate risk factors for SLE in European ancestry (rs6568431, OR = 1.2, p = 7.12 ×
10−10) [44] and in the Chinese Han population (rs548234, OR = 1.25, p = 5.18 9 10−12) [45].
Following the initial association studies, meta-analysis of this region confirmed the
association with SLE in the Chinese Han population [46]. As shown in the case of other
genes, polymorphisms in Blimp-1 are not restricted to SLE and are associated with other
autoimmune diseases as well; for example, SNP rs5458421 has been known to be associated
with SLE as well as rheumatoid arthritis (RA) [47]. The rs548234 SNP has been shown to
increase the expression of ATG5 in B cells in individuals with the homozygous risk (C/C)
allele. Due to the role of Blimp-1 in B cell differentiation, many previous studies focused on
identifying how Blimp-1 and its SNPs contribute to SLE pathogenesis in B cells. However,
it has been shown that Blimp-1 expression in total B cells in blood is extremely low, and its
expression is not affected by SNPs. Given the important role of DCs and their function in
SLE, we decided to investigate the role of Blimp-1 in DCs. Moreover, causal variants have
often been shown to directly regulate gene expression in a cell-type-specific manner;
therefore, it might be important to investigate the function of SNP in non-B cells.

Author Manuscript

Blimp-1 in dendritic cells
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Blimp-1 has been well described to function as a master regulator of plasma cell
differentiation in B cells and of cytokine expression in CD4+ T cells (reviewed in [48]). An
initial study in innate immune cells identified Blimp-1 expression as a lineage determinant
for myeloid cells in vitro [49]. In this study, Blimp-1 suppressed granulocyte lineage
differentiation and was required for monocyte differentiation. These data prompted
investigators to study whether Blimp-1 is a lineage determinant in monocytic cells such as
macrophages and DCs in vivo. In fact, following this study, Glimcher and colleagues
published that X-box binding protein (XBP)-1 expression is critical for DC differentiation in
vivo [50]. XBP-1 deficient mice possessed a reduced number of both cDCs and pDCs at
steady state and under TLR-stimulated inflammatory conditions. Although XBP-1 is not a
direct target of Blimp-1, expression of XBP-1 showed a correlation with the level of
Blimp-1 and is downstream of Blimp-1 in B cells during B cell differentiation [51]. These
observations suggest that Blimp-1 might act as a lineage determinant or survival factor for
DC differentiation.
To test whether Blimp-1 expression regulates DC differentiation in vivo, we generated
conditional knockout mice in which Blimp-1 is specifically deleted in DCs using a CD11c (a
pan DC marker in mice)-dependent CRE system. The CD11c-restricted DC-specific
Blimp-1 conditional knockout mice (Blimp-1 CKO mice) are born at Mendelian frequency
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and indistinguishable in appearance from control mice, showing normal development in
their early stages. However, the adult females spontaneously develop a lupus-like phenotype
following maturation which includes increased serum immunoglobulin level, increased antidsDNA antibodies, splenomegaly, and lymph adenopathy. They also displayed
glomerulonephritis, proteinuria without anti-dsDNA IgM antibodies at an age of 10–12
months [52]. Blimp-1-deficient DCs in these mice secreted an increased level of
proinflammatory cytokines, noticeably IL-6, following TLR4 stimulation. There are
controversial reports as to whether IL-6 is critical for follicular help T (Tfh) cell
differentiation [53, 54], but it can function as a major inducer of early differentiation of
Bcl-6+ CXCR5+ Tfh cell differentiation [55]. The induction of Bcl6, a master transcription
factor for Tfh cell differentiation, by IL-6 and its receptor require both signal transducers,
STAT1 and STAT3. In fact, one of the mechanisms of lupus development in Blimp-1 CKO
mice was an increased differentiation of follicular helper T cells (Tfh) in the spleen. The
increased Tfh cells induced germinal center (GC) formation, contributing to the generation
of autoreactive B cells in spleens of Blimp-1 CKO mice. Decreased IL-6 production in
Blimp-1 CKO mice can reverse the lupus-like phenotype by reducing Tfh cell frequency,
GC formation, and anti-dsDNA antibodies in blood. These data suggest that increased IL-6
production in Blimp-1 deficient DCs is a major pathological mechanism for autoimmune
diseases.
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We also observed that Blimp-1-deficient DCs show an increased expression of multiple
other proinflammatory cytokines and chemokines following LPS stimulation. The induction
of a negative regulator of the TLR signaling pathway, suppressor of cytokine signaling-1
(SOCS-1), was severely decreased. SOCS-1 is regulated indirectly by Blimp-1 through
regulation of microRNa Let-7c. In Blimp-1-deficient DCs, an increased level of Let-7c is
observed, leading to the downregulation of SOCS-1. Moreover, there was a direct
correlation between the level of Blimp-1 and SOCS-1, demonstrated by siRNA and
overexpression of Blimp-1 in Blimp-1-deficient DCs [56]. These data suggest that Blimp-1
can regulate cellular function through direct regulation of protein-coding genes and
indirectly through regulation of microRNA.

Author Manuscript

As described in the previous section, PRDM1 has polymorphisms that are associated with
SLE. To pursue whether a Blimp-1 polymorphism contributes to the development of SLE,
we decided to investigate whether there is different Blimp-1 expression in leukocytes of risk
allele carriers and non-risk allele carriers (controls). Interestingly, there was decreased
Blimp-1 expression in CD14+ monocyte-derived-DCs (MO-DCs) obtained from SLE risk
allele carriers compared to MO-DCs from controls. This phenotype was only observed in
young female carriers, not in male carriers or in older female carriers (age over 55 or
menopause) [56]. The reduced Blimp-1 phenotype was not observed in total B cells or
regulatory T cells (Tregs) from the SLE risk allele carrier group. Therefore, the data suggest
that the PRDM1 polymorphism might regulate Blimp-1 expression in a cell-type-dependent
manner with a gender bias toward females in which female hormones such as estrogen may
play a role in the regulatory mechanisms. Similar to mouse Blimp-1-deficient DCs, in
comparison with MO-DCs from the control group, MODCs from SLE risk carriers
expressed a higher HLA-DR level and upon TLR4 stimulation secreted an increased level of
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proinflammatory cytokine IL-6, suggesting that Blimp-1 regulates DC function in human
and mice in a comparable manner and that a low Blimp-1 level due to the risk allele in DCs
contributes the development of SLE in women.

Blimp-1 in intestinal DCs
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Previous studies have identified that Blimp-1 in T cells possesses immune regulatory
functions in the development of IBD in an animal model. [57]. However, an analysis of celltype expression specificity of genes in IBD risk loci found the strongest enrichment in DCs,
suggesting that DCs are a critical player for IBD pathogenesis [58]. We demonstrated that
Blimp-1 is highly expressed in a subset of DCs found in the intestine: CD11b+ CD103+
double-positive DCs. Moreover, this expression pattern is consistent in mouse and human
intestinal DCs, and human circulating DCs [59]. There is a specific reduction of CD11b+
CD103+ DCs in the intestine [not in peripheral lymphoid organs or mesenteric lymph nodes
(MLNs)] in Blimp-1 CKO, supporting that Blimp-1 plays a critical role in the differentiation
or survival of CD11b+ CD103+ intestinal DCs. Moreover, Blimp-1 CKO mice show an
increased susceptibility to dextran sodium sulfate (DSS)-induced IBD with high mortality
[60]. Blimp-1-deficient DCs secrete increased inflammatory cytokines, IL-1β and IL-6,
following muramyl dipeptide (MDP) stimulation. MDP is a ligand of nucleotide-binding
oligomerization domain-containing protein 2 (NOD2), and individuals with a NOD2
mutation are predisposed to IBD development [61]. There was an increased influx of
neutrophils and activated macrophages in inflamed colon of Blimp-1 CKO mice compared
to control mice. The increased IL-1β and IL-6 induces the expression of matrix
metalloproteinases (MMPs) 7, 8, and 12 in macrophages leading to exacerbated
inflammation and tissue damage. This is a novel function of intestinal DCs regulated by
Blimp-1 which has implications for human IBD pathogenesis.

Blimp-1 regulates antigen presentation
An earlier study showed that Blimp-1 can regulate antigen presentation in B cells [62].
Blimp-1 can directly suppress class II transactivator (CIITA), the master regulator of MHC
II genes. A human homologue of murine Blimp-1, PRDI-BF1, can suppress CIITA in mouse
cells, implicating a cross-species regulation. Ectopic expression of Blimp-1 in pre-B cells
decreases both endogenous CIITA and CIITA target genes, including invariant chain, H2DM, and MHC II. Thus, Blimp-1 regulates B cell differentiation and antigen presentation by
direct regulation of CIITA expression.

Author Manuscript

Blimp-1 has also been shown to regulate CIITA expression in human MO-DCs [63]. During
the immature state of MO-DCs, the transcriptional activator PU.1 binds to the promoter
region of CIITA with the help of Irf8, a critical cofactor for PU.1 binding. During the
maturation process, Blimp-1 replaces the PU.1/Irf8 complex and represses the transcription
of CIITA by recruiting co-repressor G9a and HDAC2, leading to a closed chromatin
configuration. A more recent study demonstrated that Blimp-1 might function in the antigen
presentation process in murine CD11b+ DCs [64]. Blimp-1 is highly expressed in CD11b+
DCs but is expressed in low levels in CD8+ DCs and CD11b− DCs. Its expression is
correlated with the expression of Irf4 and Cathepsin S (CtsS). Interestingly, Irf4 and Irf8
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showed an opposite expression pattern in DC subsets, and CTIIA was shown to not be
correlated with either Irf4 or Irf8 in DCs. Irf4 has been identified as a positive regulator of
Blimp-1 expression in murine Treg, and Blimp-1 expression is required for IL-10 production
in Tregs mainly in mucosal site [65]. The mechanism of Irf4-mediated Blimp-1 expression
in DCs has not been investigated yet.

Author Manuscript

Tfh cells play a key role in immune activation as a key helper T cell type for GC formation.
Tight regulation of Tfh development/resolution is critical, and dysregulation of Tfh activity
has shown to be closely related with development of SLE. There is a consistent observation
that an increased Tfh differentiation correlated with development of a lupus-like phenotype
in mice [52, 66]. In human SLE patients, there is an increased frequency of circulating Tfhlike cells in blood [67]. It is well accepted that the interaction with DCs in the T cell zones
of lymphoid organs, a fraction of activated CD4+ T cells, committed to Tfh cells
upregulating a follicle homing chemokine receptor, CXCR5, and a master transcription
factor, Bcl-6, while downregulating CCR7 [68–70]. The signals delivered from the initial
interaction with DCs determine Tfh subsets mainly through the combination of cytokines
and peptides presented by DCs which govern a signal strength of T cell receptor. Recent
data suggest that the development of Tfh cells might differ between mice and human. In
humans, TGFb works together with IL-12 and L-23 to promote Tfh differentiation; however,
TGFβ signals suppress molecules (Bcl-6, IL-21, and ICOS) in Tfh in mice [53, 71].

Author Manuscript

To further understand the mechanism of Blimp-1 in antigen presentation in DCs, we
investigated whether Blimp-1 can directly regulate expression of CtsS. There is a consensus
sequence of Blimp-1 binding motif GAAAGT in the CtsS promoter region in mouse
(−30/−25) and human (+1/+6), suggesting that CtsS is a putative target of Blimp-1 in DCs.
In fact, there was an increased expression level of CtsS in Blimp-1-deficient murine DCs
and Blimp-1 low MO-DCs from SLE risk allele carriers (manuscript in preparation).
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CtsS is a lysosomal cysteine protease that is expressed in antigen-presenting cells including
B cell, macrophages, and DCs [72]. CtsS participates in the degradation process of invariant
chain facilitating peptide loading to MHC II followed by translocation of the peptide/MHC
II complex to the cell surface [73]. CtsS also degrades phagocytosed antigens, establishing
the pool of peptides presented in MHC II [74]. Since helper T cell differentiation is
regulated not only by pro- and anti-inflammatory cytokines but also by the strength of T cell
receptor binding to MHC II [75], modulation of CtsS by Blimp-1 in DCs may regulate T cell
responses, including differentiation of Tfh cells. In fact, CtsS has become a therapeutic
target in various inflammatory disorders that are mediated by CD4+ T cells, and inhibition
of CtsS has shown to suppress disease severity in various animal models [76–78]. Oral
administration of CtsS inhibitor has shown to suppress lupus development in MRL/lpr
mouse model [79], leading us to investigate whether Blimp-1 participates in the
development of lupus through the regulation of CtsS, thereby modulating the peptide pool
which induces preferential differentiation of Tfh cells (summary Fig. 1).
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Summary and future works
Since the first discovery of Blimp-1, there is increasing appreciation of Blimp-1 as a critical
regulator in both human and mouse immune systems. Polymorphisms in Blimp-1 are
associated with autoimmune diseases, including SLE, RA, and IBD. Most studies have
previously focused on Blimp-1's role in lymphocytes and the adaptive immune response, but
it is widely accepted that Blimp-1 plays an important role in innate immune response as
well. We have identified an immune tolerogenic function of Blimp-1 in DCs, mainly
through the regulation of proinflammatory cytokines and microRNA. Blimp-1 may also
participate in the process of antigen presentation in DCs, regulating CIITA and/or CtsS
expression.

Author Manuscript

Important and interesting questions remain to be answered regarding the role of Blimp-1 in
DCs. A complete understanding of target molecules in DCs or DC subsets needs to be
addressed. It will be of interest to know whether Blimp-1 function is similar or different in
DC subsets in lymphoid organs and tissues. So far, studies of Blimp-1 have been performed
in murine cDCs and MODCs in human. Based on the broad expression of Blimp-1 in
various cell types, it will be critical to understand its role in the spectrum of DC subsets.
This will give insight into the various roles that Blimp-1 can play in multiple cell lineages.
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Tissue-dependent role of Blimp-1 in DCs. Altering the levels of Irf4, Blimp-1, and CtsS
could change the production of inflammatory cytokines and peptides presented by DCs,
modulating T cell differentiation and antigen specificity in lymphoid organs. In the intestine,
Blimp-1 regulates NOD2 expression preventing excessive production of IL-1b and IL-6.
These cytokines could induce macrophage activation and production of tissue remodeling
enzymes, leading to severe tissue damage
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Signaling pathways which are positively regulating Blimp-1 expression
Stimulus

Pathway

Cell type

Sendai virus (ds RNA virus)

TLR3/RIG-I

U20S cell line

LPS

TLR4

Mouse splenic B cells, B-1 B cells

CpG

TLR9

Mouse marginal zone B cells B-1 B cells, human naive B cells, transitional B cells, CLL B
lymphoma

a
IL2 , IL-4, and IL-10

Stat3

Mouse CD4+ T cells, CD8+ T cells, mouse splenic B cells

IL-6 and IL-21

Stat3

Human B cells

IRF4

Mouse B cells and T cells

AP-1

Raji B lymphoma, mouse splenic B cells

a

IL-2 negatively regulates Blimp-1 expression

Author Manuscript
Author Manuscript
Author Manuscript
Immunol Res. Author manuscript; available in PMC 2016 December 01.

